Apellis Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
APLS
CUSIP
03753U106
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 03753U106 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G 10.5% 2/6/2026
Event 1/31/2026
State Street Corp 13G 5.4% 5/12/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (7)
Deep Track Capital, LP 13G/A
3.6% 5/15/2026
Event 3/31/2026
RTW Investments, LP 13G/A
2.9% 5/15/2026
Event 3/31/2026
EcoR1 Capital, LLC 13G/A
2.7% 11/14/2025
Event 9/30/2025
Wellington Management Group LLP 13G/A
0.2% 4/7/2026
Event 3/31/2026
Biogen Inc. 13D/A 0% 5/14/2026
Event 5/14/2026
Morgan Stanley 13G/A
0% 6/5/2026
Event 5/31/2026
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 248 $10.2 k
2026 Q1 348 140 M $5.56 B
2025 Q4 311 126 M $3.17 B
2025 Q3 310 122 M $2.77 B
2025 Q2 277 133 M $2.30 B
2025 Q1 280 128 M $2.80 B
2024 Q4 295 127 M $4.05 B
2024 Q3 303 122 M $3.53 B
2024 Q2 295 121 M $4.65 B
2024 Q1 343 119 M $6.97 B
2023 Q4 340 120 M $7.18 B
2023 Q3 319 114 M $4.34 B
2023 Q2 375 108 M $9.81 B
2023 Q1 319 111 M $7.35 B
2022 Q4 279 105 M $5.44 B
2022 Q3 285 97.9 M $6.68 B
2022 Q2 237 91.8 M $4.15 B
2022 Q1 244 91.1 M $4.63 B
2021 Q4 211 82.7 M $3.91 B
2021 Q3 225 69.5 M $2.29 B
2021 Q2 236 65.3 M $4.13 B
2021 Q1 188 65.0 M $2.80 B
2020 Q4 182 63.9 M $3.65 B
2020 Q3 161 62.1 M $1.87 B
2020 Q2 158 61.4 M $2.00 B
2020 Q1 165 57.3 M $1.54 B
2019 Q4 162 44.6 M $1.37 B
2019 Q3 137 40.5 M $976 M
2019 Q2 103 40.5 M $1.03 B
2019 Q1 97 40.1 M $783 M
2018 Q4 97 32.5 M $429 M
2018 Q3 83 29.9 M $532 M
2018 Q2 75 29.7 M $654 M
2018 Q1 49 17.1 M $376 M
2017 Q4 46 15.7 M $340 M